Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
236 hedge funds and large institutions have $3.71B invested in Avidity Biosciences in 2024 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 85 increasing their positions, 79 reducing their positions, and 52 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 79
0.88% less ownership
Funds ownership: 107.87% → 106.99% (-0.88%)
6% less call options, than puts
Call options by funds: $19.5M | Put options by funds: $20.9M
8% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 52
4% less funds holding
Funds holding: 245 → 236 (-9)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
36% less capital invested
Capital invested by funds: $5.8B → $3.71B (-$2.09B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$90.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$44.9M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$26.1M |
| 4 |
Morgan Stanley
New York
|
+$25.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$17.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$48.7M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$29.5M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$24.8M |
| 4 |
D.E. Shaw & Co
New York
|
-$23M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$21.8M |
RNAM Hedge Fund Activity: Q4 2024 in Review
236 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q4 2024, worth a combined $3.71B — down 36% from $5.8B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of RNAM and 48 opened new positions — a net loss of 4 holders — while 79 trimmed existing stakes and 85 added.
The largest buyer was Janus Henderson Group, adding an estimated $90.1M. The largest seller was Bank of America, cutting an estimated $48.7M.
- 236 institutional investors held Avidity Biosciences (RNAM) as of Q4 2024, down from 245 in Q3 2024.
- Funds reported $3.71B of Avidity Biosciences stock for Q4 2024, down 36% quarter-over-quarter.
- 48 funds opened new Avidity Biosciences positions in Q4 2024 and 52 closed out, a net change of -4 holders.
- The largest Avidity Biosciences buyer in Q4 2024 was Janus Henderson Group, an estimated $90.1M added.
- The largest Avidity Biosciences seller in Q4 2024 was Bank of America, an estimated $48.7M sold.
Based on aggregated 13F filings for Q4 2024.